Supraclavicular lymph node metastases in cervical cancer

Area of Science:

• Oncology
• Gynecologic Oncology
• Medical Imaging

Background:

• Cervical cancer is a significant global health concern.
• Supraclavicular lymph node (SCLN) metastasis at initial diagnosis presents a unique challenge in cervical cancer management.
• Understanding prognostic factors is crucial for optimizing treatment strategies.

Purpose of the Study:

• To evaluate the survival outcomes of cervical cancer patients with primary SCLN involvement.
• To identify clinical and pathological factors associated with prognosis in this patient group.

Main Methods:

• Retrospective review of medical records from 1987-2005.
• Inclusion criteria: cervical cancer patients with histologically confirmed SCLN metastasis at primary diagnosis.
• Analysis of clinical features, pathological data, and survival rates.

Main Results:

• The 3- and 5-year survival rates for patients with SCLN metastasis were both 16.5%.
• Multivariate analysis identified serum squamous cell carcinoma antigen (SCC-Ag) levels < 15 ng/ml at diagnosis as a favorable prognostic factor (p = 0.021).
• Advanced staging, particularly when including [18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), was associated with a better prognosis (p = 0.006).

Conclusions:

• Primary SCLN metastasis in cervical cancer, though associated with poor survival, is not an absolute contraindication for curative treatment.
• FDG-PET imaging can aid in patient selection for potentially curative primary or salvage therapies.
• Further research into tailored treatment approaches for SCLN-positive cervical cancer is warranted.